IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3720
Positioning
Market Dominance
Manufacturing
Electronic Equipment
$139M
Scott A. Bibaud
Atomera Incorporated develops, commercializes, and licenses proprietary materials, processes, and technologies for the semiconductor industry in North America and the Asia Pacific. The company's lead technology is the Mears Silicon Technology, a thin film of reengineered silicon that can be applied as a transistor channel enhancement to CMOS-type transistors.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ATOM Atomera Inc | 39 | 26 | 35 | 49 | - | - | -106.9% | -92.7% | -292.4% | -70352.3% | -67258.3% | -84.7% | 0.0% | 0.0x | $139M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Atomera Inc (ATOM) receives a "Avoid" rating with a composite score of 38.6/100. It ranks #3720 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Scott A. Bibaud
Chief Executive Officer
Labor Force
20
26
35
13
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for ATOM
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ATOM.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -106.9% (sector -2.5%)
GM -292% vs sector 43%, OM -70352% vs sector 1%
Capital turnover N/A
Rev growth -85%, 10yr history
Interest coverage -482.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Atomera Inc with an Avoid rating, assigning a composite score of 38.6/100 and 1 out of 5 stars. Ranked #3720 of 7,333 stocks, ATOM falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ATOM's quality score of 26/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -106.9% (sector avg: -2.5%), gross margins of -292.4% (sector avg: 42.5%), net margins of -67258.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 35/100, ATOM appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 11.90x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Atomera Inc's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -84.7% vs. a sector average of 5.9% and a return on assets of -92.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ATOM is currently showing below-average momentum at 49/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -84.7% year-over-year, while a beta of 2.28 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
Atomera Inc registers a low stability score of 13/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.28 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
Atomera Inc's short interest score of 22/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 2.28), micro-cap liquidity risk. At $139M (micro-cap), ATOM carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Atomera Inc is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3720 of 7,333 overall (49th percentile). Key comparisons include ROE of -106.9% trailing the -2.5% sector median and operating margins of -70352.3% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ATOM currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (13) would have the largest impact on the composite score.
ROE 4210% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 788% BELOW SECTOR MEDIAN
Op. Margin 5453765% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Atomera Inc (ATOM) as Avoid with a composite score of 38.6/100 at a current price of $5.30. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (49th percentile) and value (35th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (13th percentile) and quality (26th percentile) tempers our overall conviction. We assign a No Moat rating (13/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Atomera Inc holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 38.6/100 places it at rank #3720 in our full 7,333-stock universe. At $139M in market capitalization, Atomera Inc is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -85% combined with momentum at the 49th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of -292% (-334.9pp vs sector) narrow to operating margins of -70352% (-70353.6pp vs sector) and net margins of -67258.3%, yielding a gross-to-net conversion rate of N/A%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $5.30, Atomera Inc is trading at a premium to fundamental value. Our value factor score of 35/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 11.9x, P/S of 5147.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (0% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 38.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -85% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -67258.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (26th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Very High uncertainty rating to Atomera Inc. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 2.28), current negative profitability (net margin -67258.3%), below-average price stability (13th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 2.28); current negative profitability (net margin -67258.3%); below-average price stability (13th percentile); weak quality scores (26th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 13th percentile and quality factor at the 26th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (0% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Atomera Inc's capital allocation as Poor. Key concerns include low returns on equity (-106.9%), negative profitability, weak asset returns (ROA -92.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Atomera Inc significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Atomera Inc receives a Avoid rating with a composite score of 38.6/100 (rank #3720 of 7,333). Our quantitative framework assigns a No Moat (13/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 32/100.
Our analysis does not support a constructive view on Atomera Inc at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Atomera Inc a meaningful economic moat, scoring 13/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 7/20.
The strongest moat sources are financial resilience (7/20) and growth durability (3.5/20). Interest coverage -482.8x. Rev growth -85%, 10yr history. These pillars form the core of Atomera Inc's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include margin superiority (0/20) and reinvestment efficiency (0/20). GM -292% vs sector 43%, OM -70352% vs sector 1%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Atomera Inc's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-85%) that pressure the earnings outlook. The margin cascade from -292% gross to -70352% operating to -67258.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 26th percentile.
The margin profile shows gross margins of -292%, operating margins of -70352%, net margins of -67258.3%. Return metrics include ROE of -106.9% and ROA of -92.7%. Relative to the Manufacturing sector, gross margins are 334.9 percentage points below the sector median of 43%, and ROE of -106.9% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 0%, revenue growth of -85%. The sector median D/E is 0%, putting Atomera Inc in a relatively stronger balance sheet position. Overall balance sheet health is adequate for the current business environment.
High beta of 2.28 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
LOS GATOS, CA / ACCESS Newswire / February 24, 2026 / Atomera Incorporated ("Atomera" or the "Company") (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today announced the closing of its previously announced registered direct ...
LOS GATOS, CA / ACCESS Newswire / February 23, 2026 / Atomera Incorporated ("Atomera" or the "Company") (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today announced that it has entered into a definitive securities purchase ...

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company’s quarterly sales came in at $8.37 million versus estimates of $8.75 million. Shapeways shares fell 20.8% to $2.36 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) shares climbed 62.4% to $2.16 after the company reported third-quarter results. Chemomab Therapeutics Ltd. (NASDAQ: CMMB) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease. Heron Therapeutics, Inc. (NASDAQ: HRTX) climbed 50.8% to $0.8143 after the company reported mixed third-quarter financial results and issued guidance. Kinnate Biopharma Inc. (NASDAQ: KNTE) rose 47.7% to $2.32. The company’s board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company. SciSparc Ltd. (NASDAQ: SPRC) gained 44.5% to $6.30. SciSparc said 'trial results indicated that SciSparc's proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.' Evelo Biosciences, Inc. (NASDAQ: EVLO) gained 36% to $0.47. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) climbed 34.3% to $1.75. Solid Biosciences Inc. (NASDAQ: SLDB) shares rose 32.7% to $2.83. Solid Biosciences announced IND clearance by the FDA for duchenne muscular dystrophy gene therapy candidate SGT-003. MGO Global, Inc. (NASDAQ: MGOL) shares climbed 32.4% to $0.6566 after reporting a sharp rise in third-quarter sales. Beyond Air, Inc. (NASDAQ: XAIR) gained 28% to $1.7920. AST SpaceMobile, Inc. (NASDAQ: ASTS) rose 28% to $4.8262 following third-quarter results. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 25.2% to $24.34 after the company reported a ...

Atomera reported a Q2 2025 net loss of $0.17 per share with zero revenue, continuing its pre-revenue stage. The company is focusing on semiconductor material technology licensing and developing partnerships in the chip manufacturing sector.
Above 50MA
37.18%
Net New Highs
+51081